10 unknown, 6 completed, 3 recruiting, 2 not yet recruiting. 11 Phase 2, 4 Phase 1, 1 Not applicable, 1 Phase 3.
Follow Angiogenesis Inhibitors: new trials by email Literature Review of Angiogenesis Inhibitors trials Research Report on Angiogenesis Inhibitors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma Albumin-bound Paclitaxel, Immune Checkpoint Inhibitor, Anti-angiogenic drug - Gastric Cancer, Second-line Treatment | Recruiting | Fudan University | 250 | 2025-09-01 | 2026-02-05 | |
| Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma Immunochemotherapy combined with antiangiogenic - Liver Cancer, Adult | Recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 100 | 2024-09-15 | 2025-01-16 | |
| Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis Adebrelimab + Apatinib - Unresectable Locally Advanced Non-small Cell Lung Cancer | Phase 2 | Active not recruiting | Wei Zhou | 32 | 2024-08-13 | 2024-11-22 |
| Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC Immunochemotherapy combined with antiangiogenic, Immunochemotherapy - Non-Small Cell Lung Cancer, Anti Angiogenesis | Phase 2 | Not yet recruiting | Tang-Du Hospital | 178 | 2024-06-30 | 2024-06-26 |
| PD-1/PD-L1 Inhibitors and Anti-angiogenic Therapy Combined With/Without TACE/HAIC in Patients With BCLC B/C Hepatocellular Carcinoma Beyond Up-to-7 TACE/HAIC, PD-1/PD-L1 inhibits and anti-angiogenic agents - Hepatocellular Carcinoma | Unknown | Shanghai Zhongshan Hospital | 150 | 2024-05-01 | 2024-05-21 | |
| Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers IMC-R117C, Chemotherapy drug, Kinase inhibitor - Cancer, HLA-A*02:01-positive | Phase 1 / Phase 2 | Recruiting | Immunocore Ltd | 600 | 2024-01-10 | 2026-01-28 |
| First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer Fluzoparib Capsules, Bevacizumab - Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary | Phase 2 | Not yet recruiting | Sun Yat-sen University | 44 | 2023-10-18 | 2023-10-02 |
| Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer Tislelizumab, Pemetrexed, Bevacizumab - Non-Small Cell Lung Cancer | Phase 1 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 30 | 2022-08-01 | 2022-07-13 |
| Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations Osimertinib, Bevacizumab Biosimilar IBI305, Carboplatin - Non Small Cell Lung Cancer | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 50 | 2021-08-01 | 2022-08-19 |
| Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer Antiangiogenesis Agents, Immune checkpoint inhibitor - Advanced Non-squamous Non-small Cell Lung Cancer | Unknown | Peking University Cancer Hospital & Institute | 126 | 2021-03-03 | 2021-02-24 | |
| Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC Anti-angiogenic agents plus anti-PD-1/PD-L1 antibodies - Hepatocellular Carcinoma | Unknown | Shanghai Zhongshan Hospital | 200 | 2020-12-23 | 2021-07-26 | |
| Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma Camrelizumab, Albumin Paclitacxel, Apatinib - Adenocarcinoma of the Lung | Phase 2 | Unknown | Hunan Cancer Hospital | 63 | 2020-08-26 | 2022-12-02 |
| Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases With Perilesional Edema in NSCLC Anlotinib, Stereotactic Radiosurgery - Stereotactic Body Radiation Therapy | Phase 2 | Unknown | Peking University Third Hospital | 50 | 2019-12-24 | 2020-03-04 |
| Efficacy and Safety Analysis of ICIs Plus Angiogenesis Inhibitors for Treatment of Advanced NSCLC in Elderly Patients Immune checkpoint inhibitors plus angiogenesis inhibitors, Immune checkpoint inhibitors without angiogenesis inhibitors - NSCLC | Completed | Suzhou Municipal Hospital | 79 | 2019-01-01 | 2023-01-19 | |
| Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma Nivolumab, Bevacizumab - Recurrent Adult Brain Tumor | Phase 2 | Completed | Ulrik Lassen | 40 | 2018-10-01 | 2025-07-24 |
| Multimodal Image Study of Retinal Inflammation Markers After Corticoid and Antiangiogenic Treatment in Pacients With Diabetic Macular Edema Antiangiogenic Agents, Corticosteroid - Diabetic Macular Edema | Unknown | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 80 | 2018-05-23 | 2018-07-11 | |
| Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer EGFR-TK Inhibitor, Anti-Angiogenic Drugs - Non Small Cell Lung Cancer | Phase 2 | Unknown | Xinqiao Hospital of Chongqing | 100 | 2018-05-01 | 2018-03-09 |
| Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases in NSCLC Anlotinib - Stereotactic Body Radiation Therapy | Completed | Peking University Third Hospital | 30 | 2017-01-15 | 2021-06-03 | |
| Bevacizumab 0.500MG Intravitreal There Isn't Lower Than 0.625MG in the Treatment of ROP Type 1 Injection of bevacizumab intravitreal (Avastin) - Retinopathy of Prematurity | Not applicable | Unknown | Universidad Autonoma de San Luis Potosí | 60 | 2013-09-01 | 2014-03-18 |
| TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer AMG 386, AMG 386 Placebo, Paclitaxel - Fallopian Tube Cancer, Ovarian Cancer | Phase 3 | Completed | Amgen | 919 | 2010-11-01 | 2016-12-15 |
Showing 20 of 23. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (4) · Carcinoma, Hepatocellular (3) · Fallopian Tube Neoplasms (2) · Neoplasms (2) · Ovarian Neoplasms (2) · Adenocarcinoma of Lung (1) · Brain Neoplasms (1) · Port-Wine Stain (1) · Radiation Pneumonitis (1) · Retinopathy of Prematurity (1) · Stomach Neoplasms (1)
Amgen (3) · Peking University Third Hospital (2) · Shanghai Zhongshan Hospital (2) · Tianjin Medical University Cancer Institute and Hospital (2) · Fudan University (1) · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1) · Hunan Cancer Hospital (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Immunocore Ltd (1) · Peking University Cancer Hospital & Institute (1) · Sun Yat-sen University (1) · Suzhou Municipal Hospital (1) · Tang-Du Hospital (1) · Ulrik Lassen (1) · Universidad Autonoma de San Luis Potosí (1)
China (13) · Italy (3) · Spain (3) · Australia (2) · Belgium (2) · Mexico (2) · Brazil (1) · Bulgaria (1) · Canada (1) · Chile (1) · Croatia (1) · Czechia (1) · Denmark (1) · Estonia (1) · France (1)
Hongqing Zhuang, doctor (1) · Hui-Chuan Sun, MD, PhD (1) · Jing Xue (1) · John S Nelson, M.D,PhD (1) · Laura Gramantieri (1) · Linna Liu (1) · Rangel Ch Martha, Speciality (1) · Ulrik Lassen, MD, PHD (1) · Wei Zhou (1)
PMID 17557949, PMID 26304872, PMID 27029706, PMID 33294918, PMID 37185961, PMID 38261958
2017 (1), 2023 (1)